Tag: pharma QA

Preparing for Re-Inspection and Verification of GMP CAPA Step-by-Step Guide to Preparing for Re-Inspection and Verification of GMP CAPA Pharmaceutical manufacturers operating under the regulatory frameworks of the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and other global authorities must navigate complex…

Read More “Preparing for Re-Inspection and Verification of GMP CAPA” »

How to Use Mock PAIs to De-Risk Upcoming Product Approvals Effective Use of Mock PAIs to Mitigate Risks in Upcoming Product Approvals For pharmaceutical manufacturers in the US, UK, and EU, successfully navigating a pre-approval inspection (PAI) is a pivotal step toward securing product authorization. However, real PAIs conducted by regulatory agencies such as the…

Read More “How to Use Mock PAIs to De-Risk Upcoming Product Approvals” »

Aligning Validation and GMP Readiness Before Regulatory Inspections Strategically Aligning Validation and GMP Readiness for Regulatory Inspections The pharmaceutical industry faces strict oversight from regulators such as the FDA, EMA, MHRA, and PIC/S authorities. Achieving robust GMP inspection readiness necessitates a comprehensive alignment of validation efforts with overarching quality management systems. In practical terms, this…

Read More “Aligning Validation and GMP Readiness Before Regulatory Inspections” »

Demonstrating Robust Deviation and CAPA Systems During Inspections Step-by-Step Guide to Demonstrating Robust Deviation and CAPA Systems During GMP Inspections The ability to effectively manage deviations and implement corrective and preventive actions (CAPA) is a critical aspect of pharmaceutical quality systems. During a regulatory inspection, such as an FDA 483 issuance or a comprehensive GMP…

Read More “Demonstrating Robust Deviation and CAPA Systems During Inspections” »

Aligning Sponsor and CMO Responses to Shared GMP Deficiencies Effective Coordination of Sponsor and CMO Responses to Shared GMP Deficiencies Regulatory inspections such as FDA 483 observations are critical events for pharmaceutical sponsors and Contract Manufacturing Organizations (CMOs). Both parties share a responsibility to address GMP inspection findings effectively to maintain product quality and regulatory…

Read More “Aligning Sponsor and CMO Responses to Shared GMP Deficiencies” »

How to Recover From a Failed FDA PAI in Pharma Manufacturing Step-by-Step Guide: How to Recover From a Failed FDA PAI in Pharmaceutical Manufacturing Pharmaceutical manufacturers facing a failed FDA Pre-Approval Inspection (PAI) may encounter significant operational, regulatory, and reputational risks. A failed PAI usually results from documented non-compliances observed during the GMP inspection, often…

Read More “How to Recover From a Failed FDA PAI in Pharma Manufacturing” »

Building a 12-Month GMP Remediation Roadmap After a Major Inspection Step-by-Step Guide to Building a 12-Month GMP Remediation Roadmap After a Major Inspection Pharmaceutical manufacturers facing an FDA 483 observation or a warning letter after a GMP inspection must act decisively and systematically to restore compliance and ensure future inspection readiness. This article outlines a…

Read More “Building a 12-Month GMP Remediation Roadmap After a Major Inspection” »

Using External Consultants for GMP Remediation: When and How Leveraging External Consultants for Effective GMP Remediation: A Step-by-Step Guide Good Manufacturing Practice (GMP) compliance remains a cornerstone for pharmaceutical manufacturers seeking to ensure product quality, patient safety, and regulatory adherence. Receiving a FDA 483 observation or other regulatory inspection findings requires a systematic and effective…

Read More “Using External Consultants for GMP Remediation: When and How” »

Leveraging GMP Inspection Outcomes to Strengthen the Quality Culture How to Leverage GMP Inspection Outcomes to Strengthen Your Quality Culture Pharmaceutical manufacturers operating across the US, UK, and EU continuously face regulatory scrutiny through GMP inspections, audits, and associated follow-up actions such as FDA 483 observations or warning letters. These regulatory inspections serve a crucial…

Read More “Leveraging GMP Inspection Outcomes to Strengthen the Quality Culture” »

Reporting GMP Inspection Outcomes to Senior Leadership and the Board Step-by-Step Guide to Reporting GMP Inspection Outcomes to Senior Leadership and the Board Pharmaceutical manufacturers subject to GMP inspection initiatives from regulatory authorities such as the FDA, EMA, and MHRA must ensure rigorous communication of inspection outcomes within their organizations. Particularly critical is the reporting…

Read More “Reporting GMP Inspection Outcomes to Senior Leadership and the Board” »